Literature DB >> 17008668

Meningococcal disease and its management in children.

C Anthony Hart1, Alistair P J Thomson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17008668      PMCID： PMC1584345          DOI： 10.1136/bmj.38968.683958.AE

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  23 in total

1.  The management of fever and petechiae: collaborative studies are needed.

Authors:  C Richards; A Thimm; J Clark; A P Thomson; T Newton; F A Riordan
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

2.  Mortality in severe meningococcal disease.

Authors:  K Thorburn; P Baines; A Thomson; C A Hart
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

3.  Meningococcal bacterial DNA load at presentation correlates with disease severity.

Authors:  S J Hackett; M Guiver; J Marsh; J A Sills; A P J Thomson; E B Kaczmarski; C A Hart
Journal:  Arch Dis Child       Date:  2002-01       Impact factor: 3.791

4.  Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group.

Authors:  B Derkx; J Wittes; R McCloskey
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

5.  Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit.

Authors:  Stephen J Gray; Caroline L Trotter; Mary E Ramsay; Malcolm Guiver; Andrew J Fox; Raymond Borrow; Richard H Mallard; Edward B Kaczmarski
Journal:  J Med Microbiol       Date:  2006-07       Impact factor: 2.472

Review 6.  Cytokines, chemokines and other effector molecules involved in meningococcal disease.

Authors:  S J Hackett; A P J Thomson; C A Hart
Journal:  J Med Microbiol       Date:  2001-10       Impact factor: 2.472

7.  Neurodevelopmental outcome in meningococcal disease: a case-control study.

Authors:  J M Fellick; J A Sills; O Marzouk; C A Hart; R W Cooke; A P Thomson
Journal:  Arch Dis Child       Date:  2001-07       Impact factor: 3.791

8.  The child with a non-blanching rash: how likely is meningococcal disease?

Authors:  L C Wells; J C Smith; V C Weston; J Collier; N Rutter
Journal:  Arch Dis Child       Date:  2001-09       Impact factor: 3.791

Review 9.  New therapies and vaccines for meningococcal disease.

Authors:  E D Carrol; A P Thomson; C A Hart
Journal:  Expert Opin Investig Drugs       Date:  2001-08       Impact factor: 6.206

10.  Improved case confirmation in meningococcal disease with whole blood Taqman PCR.

Authors:  S J Hackett; E D Carrol; M Guiver; J Marsh; J A Sills; A P J Thomson; E B Kaczmarski; C A Hart
Journal:  Arch Dis Child       Date:  2002-06       Impact factor: 3.791
View more
  10 in total

Review 1.  Challenges and opportunities for meningococcal vaccination in the developing world.

Authors:  Rouba Shaker; Danielle Fayad; Ghassan Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2018-02-23       Impact factor: 3.452

2.  Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy.

Authors:  Antonia Bouts; Leo Monnens; Jean-Claude Davin; Geertrude Struijk; Lodewijk Spanjaard
Journal:  Pediatr Nephrol       Date:  2011-06-05       Impact factor: 3.714

3.  An Adolescent Boy Presenting with Complicated Meningococcal Meningitis Serogroup A: What Is the State of Community Awareness for This Serious Disease?

Authors:  Saliha Kanik-Yuksek; Hasan Tezer; Aslinur Ozkaya-Parlakay; Hulya Sayed-Oskovi; Meral Turan
Journal:  Iran J Public Health       Date:  2014-09       Impact factor: 1.429

4.  Multidisciplinary analysis of invasive meningococcal disease as a framework for continuous quality and safety improvement in regional Australia.

Authors:  Kathryn A Taylor; David N Durrheim; Tony Merritt; Peter Massey; John Ferguson; Nick Ryan; Carolyn Hullick
Journal:  BMJ Open Qual       Date:  2018-02-07

5.  A systematic review of the diagnostic accuracy of Loop-mediated-isothermal AMPlification (LAMP) in the diagnosis of invasive meningococcal disease in children.

Authors:  Thomas Waterfield; Derek Fairley; Bronagh Blackwood; James McKenna; Michael D Shields
Journal:  BMC Pediatr       Date:  2019-02-07       Impact factor: 2.125

6.  [Hemorrhagic skin lesions associated with infections].

Authors:  R Elling; M Hufnagel; P Henneke
Journal:  Monatsschr Kinderheilkd       Date:  2012-06-10       Impact factor: 0.323

7.  Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol.

Authors:  Helen S Marshall; Prabha H Andraweera; Bing Wang; Mark McMillan; Ann P Koehler; Noel Lally; Sara Almond; Emma Denehy; Michele A'Houre; Lynne C Giles; Louise Flood
Journal:  Hum Vaccin Immunother       Date:  2021-01-11       Impact factor: 3.452

8.  Nonspecific symptoms dominate at first contact to emergency healthcare services among cases with invasive meningococcal disease.

Authors:  Nichlas Hovmand; Helle Collatz Christensen; Lene Fogt Lundbo; Håkon Sandholdt; Gitte Kronborg; Perle Darsø; Jacob Anhøj; Stig Nikolaj Fasmer Blomberg; Asmus Thun Bisgaard; Thomas Benfield
Journal:  BMC Fam Pract       Date:  2021-11-30       Impact factor: 2.497

9.  Pre-hospital antibiotic treatment and mortality caused by invasive meningococcal disease, adjusting for indication bias.

Authors:  Emilio Perea-Milla; Julián Olalla; Emilio Sánchez-Cantalejo; Francisco Martos; Petra Matute-Cruz; Guadalupe Carmona-López; Yolanda Fornieles; Aurelio Cayuela; Javier García-Alegría
Journal:  BMC Public Health       Date:  2009-04-03       Impact factor: 3.295

10.  AMEND study protocol: a case-control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adults.

Authors:  Helen Marshall; Mark McMillan; Bing Wang; Robert Booy; Hossein Afzali; Jim Buttery; Christopher C Blyth; Peter Richmond; David Shaw; David Gordon; Belinda Barton
Journal:  BMJ Open       Date:  2019-12-29       Impact factor: 2.692
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.